Hepion Pharmaceuticals Inc (HEPA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hepion Pharmaceuticals Inc (HEPA) has a cash flow conversion efficiency ratio of -0.125x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-332.77K) by net assets ($2.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Hepion Pharmaceuticals Inc stock valuation for the company's overall valuation and market capitalisation.
Hepion Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Hepion Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hepion Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hepion Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Hepion Pharmaceuticals Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Radaan Mediaworks India Limited
NSE:RADAAN
|
0.196x |
|
Clasquin
PA:ALCLA
|
-0.099x |
|
BLOCKMATE VENTURES INC.
F:8MH
|
0.073x |
|
TROC DE L'ILE SA
PA:MLTRO
|
-0.160x |
|
Smtrack Bhd
KLSE:0169
|
0.003x |
|
CLARITY METALS CORP.
F:27G0
|
0.146x |
|
MW Trade S.A.
WAR:MWT
|
-0.050x |
|
Current Water Technologies Inc
V:WATR
|
-0.016x |
Annual Cash Flow Conversion Efficiency for Hepion Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Hepion Pharmaceuticals Inc from 2012 to 2025. View current stock price of Hepion Pharmaceuticals Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.67 Million | $-3.27 Million | -1.226x | -112.54% |
| 2024-12-31 | $-1.86 Million | $-18.22 Million | 9.776x | +274.08% |
| 2023-12-31 | $7.28 Million | $-40.89 Million | -5.616x | -700.86% |
| 2022-12-31 | $49.86 Million | $-34.96 Million | -0.701x | -108.85% |
| 2021-12-31 | $93.00 Million | $-31.22 Million | -0.336x | +15.84% |
| 2020-12-31 | $40.52 Million | $-16.17 Million | -0.399x | +17.65% |
| 2019-12-31 | $15.62 Million | $-7.57 Million | -0.484x | +93.88% |
| 2018-12-31 | $1.98 Million | $-15.65 Million | -7.922x | -257.35% |
| 2017-12-31 | $3.70 Million | $-8.21 Million | -2.217x | +82.36% |
| 2016-12-31 | $1.32 Million | $-16.56 Million | -12.565x | -346.74% |
| 2015-12-31 | $3.44 Million | $-9.67 Million | -2.813x | -705.22% |
| 2014-12-31 | $-2.93 Million | $-1.36 Million | 0.465x | 0.00% |
| 2013-12-31 | $-2.93 Million | $-1.36 Million | 0.465x | +81819.04% |
| 2012-12-31 | $-140.50K | $-79.70 | 0.001x | -- |
About Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as … Read more